The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations. Sanofi, Empowering Life.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

18 years of age and unsolicited safety data from approximately 38,000 trial participants who have been followed for a median of two months following the second dose of the vaccine candidate. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment. About the Study.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

This trial evaluated return of bowel function in adult patients undergoing open-heart surgery with cardiopulmonary bypass. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Tom Hallam, Ph.D.,

Trials 52

Trials Containment Clinical Trials Clinical Trials 52

The Pharma Data

MAY 7, 2021

population in just a few months, the BLA submission is an important cornerstone of achieving long-term herd immunity and containing COVID-19 in the future,” said Ugur Sahin, M.D., regulators to seek approval of our COVID-19 vaccine based on our pivotal Phase 3 trial and follow-up data.”. CEO and Co-founder of BioNTech. “We

Licensing 52

Licensing Licensing Vaccination Vaccine 52

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations. www.sec.gov.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

Analysis evaluated 94 confirmed cases of COVID-19 in trial participants. Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints. Pfizer Inc.

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

The Pharma Data

NOVEMBER 10, 2020

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.

Clinical Trials 40

Clinical Trials Clinical Trials Production Development 40

The Pharma Data

AUGUST 20, 2020

Phase 1 trial for the BNT162b2 vaccine candidate, which at 30 ?g The companies are continuing to analyze data from the Phase 1 trials in the U.S. The totality of the clinical and preclinical data informed Pfizer and BioNTech’s decision to select BNT162b2 as the lead candidate to advance into pivotal trials. and Germany.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 11, 2020

All trial participants will continue to be monitored to assess long-term protection and safety for an additional two years after their second dose. The participants in our COVID-19 vaccine clinical trial are courageous volunteers who have made a personal and important choice to help make a difference during this pandemic.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 3, 2021

Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. Based on the strong scientific rationale for telaglenastat in KEAP1/NRF2 mutant non-small cell lung cancer patients, and the safety profile observed in CANTATA, we remain dedicated to advancing our randomized KEAPSAKE trial.”.

Trials 52

Trials Clinical Trials Clinical Trials Containment 52

The Pharma Data

OCTOBER 25, 2020

mRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at the 100 µg dose level in the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-Looking Statements.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Development 52

The Pharma Data

OCTOBER 28, 2020

We appreciate the confidence of the MHLW in Moderna and mRNA-1273, which we hope will help address the pandemic, especially given the encouraging data we have recently published together with the NIH related to the clinical trial in the elderly and older adult population,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We

Vaccination 40

Vaccination Vaccine Manufacturing Clinical Trials 40

The Pharma Data

FEBRUARY 22, 2021

Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments. .

Production 52

Production Manufacturing Development Vaccination 52

The Pharma Data

APRIL 27, 2021

The information contained in this release is as of April 19, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. About BioNTech.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Trials 52

The Pharma Data

JULY 21, 2021

In a clinical study, adverse reactions in adolescents 12 through 15 years of age included pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever 3 (24.3%), joint pain (20.2%), injection site swelling (9.2%), injection site redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%).

Manufacturing 52

Manufacturing Vaccination Vaccine Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. Safe Harbor Statement. Source link.

Containment 40

Containment Sales Development Clinical Trials 40

The Pharma Data

MAY 6, 2021

Severe allergic reactions have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials. The information contained in this release is as of May 6, 2021. Pfizer Disclosure Notice.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 15, 2020

A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. Forward-Looking Statements.

Containment 52

Containment Protein Engineer Sales 52

The Pharma Data

DECEMBER 1, 2020

This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. will mark the first time citizens outside of the trials will have the opportunity to be immunized against COVID-19,” said Ugur Sahin, M.D., The Emergency Use Authorization in the U.K.

Vaccination 40

Vaccination Vaccine Manufacturing Clinical Trials 40

The Pharma Data

JANUARY 19, 2021

A preliminary prospectus supplement relating to, and describing the terms of, the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov. The offering will be made only by means of the prospectus and prospectus supplement that form a part of the registration statement.

Containment 52

Containment Genome Genomics Sales 52

The Pharma Data

JANUARY 20, 2021

A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Sales 52

Pfizer

OCTOBER 18, 2022

Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments. . COVID-19, Vaccines. 09.24.2022. Leadership. 09.22.2022. Medicines, Research. 09.16.2022.

Vaccination 40

Vaccination Vaccine Gene Therapy Medicine 40

The Pharma Data

DECEMBER 8, 2020

Recently released interim Phase 1 further indicates that 90 days following the second vaccination, trial participants retained high levels of neutralizing antibodies, suggesting that mRNA-1273 can generate durable neutralizing antibodies across all age groups including in older and elderly adults. Department of Health and Human Services.

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

The Pharma Data

SEPTEMBER 10, 2020

We are proud to share the latest insights on our cancer medicines at ESMO this year, including data from the CROWN trial examining the first-line use of our third-generation biomarker-driven therapy in ALK-positive non-small cell lung cancer.”. Investigator-Sponsored Studies and Clinical Research Collaborations. . Sridhar S. . .

Production 52

Production Medicine Containment Development 52

Pfizer

FEBRUARY 28, 2023

In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer DISCLOSURE NOTICE : The information contained in this statement is as of February 27, 2023.

Containment 40

Containment Vaccination Vaccine Development 40

The Pharma Data

JANUARY 5, 2021

A prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

Sales 52

Sales Gene Therapy Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus, when available, may also be obtained from J.P.

Clinical Trials 40

Clinical Trials Clinical Trials Clinical Development Antibody 40

The Pharma Data

MARCH 4, 2021

Together we generated positive Phase 2 ELEKTRA study data, and as a result, soticlestat is poised to enter two pivotal trials,” said Andy Plump, M.D., Securities and Exchange Commission, available on Takeda’s website at: [link] or at www.sec.gov. “I would like to thank Ovid for their thoughtful and productive collaboration.

Development 52

Development Containment Medicine Clinical Trials 52

The Pharma Data

APRIL 28, 2021

Fosmanogepix is currently in Phase 2 clinical trials evaluating the safety and efficacy of both intravenous (IV) and oral formulations for the treatment of patients with life-threatening invasive fungal infections caused by molds, yeasts and rare molds (e.g., The information contained in this release is as of April 28, 2021.

Clinical Trials 40

Clinical Trials Clinical Trials Containment In-Vitro 40

The Pharma Data

DECEMBER 14, 2020

Many drugs fail in clinical trials because of their low blood brain barrier permeability. If we can compress the time to clinical trials, and de-risk LP-184, we can save years of research and millions of dollars in developing treatments for GBM and potentially other CNS and brain cancers.” Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

NOVEMBER 16, 2020

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s development of a potential vaccine (mRNA-1273) against the novel coronavirus, the conditions under which mRNA-1273 can be shipped, stored and administered, and the U.S.

Vaccination 52

Vaccination Vaccine Containment Pharmacy 52

The Pharma Data

DECEMBER 2, 2020

PFIZER DISCLOSURE NOTICE: The information contained in this release is as of November 23, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. About the BASIS study. Source: Pfizer Inc. . Posted: December 2020.

Containment 52

Containment Development Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 16, 2021

Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Production 40

Production Manufacturing Development Vaccination 40

The Pharma Data

JANUARY 19, 2021

LLC, 430 Park Avenue 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996, or by email at placements@hcwco.com, or at the SEC’s website at www.sec.gov. This press release contains forward-looking statements. The securities referred to in this press release will be offered only by means of a prospectus filed with the SEC.

Regulation 52

Regulation Containment Development Clinical Trials 52

The Pharma Data

FEBRUARY 8, 2021

Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% DISCLOSURE NOTICE : The information contained in this release is as of February 5, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

HR 52

HR Clinical Trials Clinical Trials Containment 52

The Pharma Data

NOVEMBER 19, 2020

Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements.

Containment 52

Containment Marketing Sales Clinical Trials 52

The Pharma Data

AUGUST 5, 2020

Based on the positive preclinical data recently published in the peer reviewed journal Nature , the Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Learn more at www.janssen.com.

Vaccination 52

Vaccination Vaccine Production Regulation 52